Savara (SVRA) Asset Writedowns and Impairment (2012 - 2018)
Savara (SVRA) posted quarterly Asset Writedowns and Impairment of $21.7 million for Q1 2018, up 21037.15% quarter-over-quarter from $102625.0 in Q4 2012.
Powered by 
Analysis
Savara (SVRA) Asset Writedowns and Impairment (2012 - 2018) Analysis & Trends
Savara (SVRA) has reported Asset Writedowns and Impairment for 2 consecutive years, with $21.7 million the latest figure, recorded in Q1 2018.
- In Q1 2018, Asset Writedowns and Impairment changed N/A year-over-year to $21.7 million; the TTM figure through Dec 2018 stood at $21.7 million (changed N/A YoY), while the FY2018 annual figure was $21.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment grew to $21.7 million in Q1 2018 per SVRA's latest filing, from $102625.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $21.7 million in Q1 2018 and bottomed at $21.7 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - |